Furthermore, the efficacy of chidamide in combination with PET regimens (CPET) has been evaluated in several clinical trials (18), further supporting the higher mutation frequency of TET2 and DNMT3A in AITL. Here, TET2 is linked to angioimmunoblastic T-cell lymphoma.